Biomarkers in cervical screening: Quantitative reverse transcriptase PCR analysis of P16 INK4a expression

European Journal of Cancer Prevention

Volumn 19, Issue 1, 2010, Pages 35-41

  Boulet, Gaëlle A V ^a   Horvath, Caroline A J ^a   Depuydt, Christophe E ^b   Bogers, Johannes J ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Laboratory for Clinical Pathology   (Belgium)

Author keywords

Biomarker; Cervical cancer; Human papillomavirus; Liquid based cervical cytology; P16INK4a; Quantitative real time PCR

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; CYTODIAGNOSIS; CYTOLOGY; DYSPLASIA; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; WART VIRUS;

BIOLOGICAL MARKERS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; GENE EXPRESSION; GENES, P16; GENETIC TESTING; HELA CELLS; HUMANS; MODELS, BIOLOGICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS;

EID: 75149186107     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32833233d4     Document Type: Article

References (47)

1. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J (2004). Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 96:280-293. (Pubitemid 38256273)
2. Arbyn M, Paraskevaidis E, Martin-Hirsch P, PrendivilleW, Dillner J (2005). Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 99:7-11.
3. Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P, Depuydt C (2009). Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 18:321-330.
4. Baldwin P, Laskey R, Coleman N (2003). Translational approaches to improving cervical screening. Nat Rev Cancer 3:217-226.
5. Bernard PS, Wittwer CT (2002). Real-time PCR technology for cancer diagnostics. Clin Chem 48:1178-1185.
6. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244-265. (Pubitemid 34293391)
7. Boulet G, Horvath C, Vanden Broeck D, Sahebali S, Bogers J (2007). Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol 39:2006-2011.
8. Branca M, Ciotti M, Santini D, Di Bonito L, Giorgi C, Benedetto A, et al. (2004). p16(INK4A) expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 23:354-365.
9. Cuschieri K, Wentzensen N (2008). Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 17:2536-2545.
10. Cuschieri KS,Whitley MJ, Cubie HA (2004). Human papillomavirus type specific DNA and RNA persistence - implications for cervical disease progression and monitoring. J Med Virol 73:65-70.
11. Cuschieri KS, Beattie G, Hassan S, Robertson K, Cubie HA (2005). Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid-based cytology medium. J Virol Methods 124:211-215.
12. Depuydt CE, Benoy IH, Bailleul EJ, Vandepitte J, Vereecken AJ, Bogers JJ (2006). Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology 17:374-381.
13. Depuydt CE, Boulet GA, Horvath CA, Benoy IH, Vereecken AJ, Bogers JJ (2007). Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med 11:881-891.
14. Dimulescu II, Unger ER, Lee DR, Reeves WC, Vernon SD (1998). Characterization of RNA in cytologic samples preserved in a methanol-based collection solution. Mol Diagn 3:67-71.
15. Ferlay J, Bray F, Pisani P, Parkin DM (2001). GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide, version 1.0. Lyon: IARC Press.
16. Habis AH, Vernon SD, Lee DR, Verma M, Unger ER (2004). Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. Cancer Epidemiol Biomarkers Prev 13:492-496.
17. Holladay EB, Logan S, Arnold J, Knesel B, Smith GD (2006). A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/ neoplasia. Cancer 108:451-461.
18. Horvath CA, Boulet G, Sahebali S, Depuydt C, Vermeulen T, Vanden Broeck D, et al. (2008). Effect of fixation on RNA integrity in a liquid-based cervical cytology setting. J Clin Pathol 61:132-137.
19. Kitchener HC, Castle PE, Cox TJ (2006). Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 24S3:S3/63-S3/70.
20. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. (2001). Overexpression of p16(INK4a) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92:276-284.
21. Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, et al. (2005). DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 97:908-915.
22. Ling J,Wiederkehr U, Cabiness S, Shroyer KR, Robinson PJ (2008). Application of flow cytometry for biomarker-based cervical cancer cells detection. Diagn Cytopathol 36:76-84.
23. Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ (2009). Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol 511:333-359.
24. Meyer JL, Hanlon DW, Andersen BT, Rasmussen OF, Bisgaard K (2007). Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: correlation with biopsy follow-up results. Cancer 1 1:83-92.
25. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B (2005). Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 14:367-372.
26. Molden T, Kraus I, Skomedal H, Nordstrøm T, Karlsen F (2007). PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Methods 142:204-212.
27. Murthy NS, Mathew A (2000). Risk factors for pre-cancerous lesions of the cervix. Eur J Cancer Prev 9:5-14.
28. Nakagawa S, Yoshikawa H, Yasugi T, Kimura M, Kawana K, Matsumoto K, et al. (2000). Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J Med Virol 6 2:251-258.
29. Naucler P, Ryd W, Tö rnberg S, Strand A, Wadell G, Elfgren K, et al. (2007). Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 18:1589-1597.
30. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. (2004). The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 30:205-211.
31. Parkin DM, Bray F (2006). Chapter 2: the burden of HPV-related cancers. Vaccine 24:S11-S25.
32. Payne N, Chilcott J, McGoogan E (2000). Liquid-based cytology for cervical screening. Cytopathology 11:469-470.
33. Powell N, Smith K, Fiander A (2006). Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J Virol Methods 137:58-62.
34. Ronco G, Brezzi S, Carozzi F, Dalla Palma P, Giorgi-Rossi P, Minucci D, et al.; NTCC study group (2007). The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecol Oncol 107 (Suppl 1):S230-S232. (Pubitemid 47483863)
35. Sahebali S, Depuydt CE, Segers K, Moeneclaey LM, Vereecken AJ, Van Marck E, et al. (2004). p16INK4a as an adjunct marker in liquid-based cervical cytology. Int J Cancer 108:871-876.
36. Sahebali S, Depuydt CE, Boulet GA, Arbyn M, Moeneclaey LM, Vereecken AJ, et al. (2006). Immunocytochemistry in liquid-based cervical cytology: analysis of clinical use following a cross-sectional study. Int J Cancer 118:1254-1260.
37. Saqi A, Pasha TL, McGrath CM, Yu GH, Zhang P, Gupta P (2002). Overexpression of p16INK4A in liquid-based specimens (SurePath) as a maker of cervical dysplasia and neoplasia. Diagn Cytopathol 27:365-370.
38. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. (2002). The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287:2114-2119.
39. Steinau M, Rajeevan MS, Unger ER (2006). DNA and RNA references for qRTPCR in exfoliated cervical cells. J Mol Diagn 8:113-118.
40. Tarkowski TA, Rajeevan MS, Lee DR, Unger ER (2001). Improved detection of viral RNA isolated from liquid-based cytology samples. Mol Diagn 6:125-130. The Atypical Squamous Cells of Undetermined Significance/Low-Grade
41. Squamous Intraepithelial Lesions Triage Study (ALTS) Group (2000). Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 92:397-402.
42. Tsoumpou I, Arbyn M, Kyrgiou M,Wentzensen N, Koliopoulos G, Martin-Hirsch P, et al. (2009). p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 35:210-220.
43. Wentzensen N, Bergeron C, Cas F, Eschenbach D, Vinokurova S, von Knebel Doeberitz M (2005). Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer 105:461-467.
44. Wilhelm J, Hahn M, Pingoud A (2000). Influence of DNA target melting behavior on real-time PCR quantification. Clin Chem 46:1738-1743.
45. Wright TC (2007). Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obstet Gynecol 50:313-323.
46. Yildiz IZ, Usubütün A, Firat P, Ayhan A, Kücükali T (2007). Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. Pathol Res Pract 203:445-449.
47. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, et al. (2004). HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 5 9:543-553.